Calaspargase Pegol-mknl

Category: Cancer



Calaspargase Pegol-mknl Overview

Calaspargase pegol-mknl (trade name Asparlas) is a drug for the treatment of acute lymphoblastic leukemia (ALL). It is approved by the Food and Drug Administration for use in the United States as a component of a multi-agent chemotherapeutic regimen for ALL in pediatric and young adult patients aged 1 month to 21 years.[1] Calaspargase pegol is an engineered protein consisting of the E. coli-derived enzyme L-asparaginase II conjugated with succinimidyl carbonate monomethoxypo...

Read more Calaspargase Pegol-mknl Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Calaspargase_pegol-mknl

Recent Calaspargase Pegol-mknl Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Calaspargase Pegol-mknl
  • Injection: 3750units/5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Calaspargase Pegol-mknl or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 20 November 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA